Please login to the form below

Not currently logged in
Email:
Password:

Vertex prepares to launch breakthrough cystic fibrosis treatment in Europe

EC clears personalised drug that tackles genetic cause of condition

The European Commission (EC) has approved Vertex Pharmaceuticals' personalised medicine Kalydeco, clearing the company to launch the drug as the first treatment available in the region to target the cause of cystic fibrosis.

Kalydeco (ivacaftor) is now available for a certain subset of people with cystic fibrosis – people who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

There are thought to be around 1,100 people in Europe who have this specific mutation, meaning Vertex was able to apply for orphan drug status during its marketing authorisation application.

Despite its small target population, the drug is a breakthrough product in cystic fibrosis as it is able to tackle the genetic malfunction behind the condition, rather than simply alleviate symptoms like other available treatments.

Taken twice-daily in tablet form, it restores the function of the mutated CFTR protein, which regulates salt and water transport in the body.

When this protein malfunctions, as happens in people with cystic fibrosis, too much salt and water can be held in cells, leading to a build up of a thick mucus in the body's various passageways, leading to breathing problems and recurring chest and lung infections.

Current medications to treat cystic fibrosis include bronchodilator drugs to help open airways and DNase to break down mucus, but Kalydeco is the first to target the actual mechanism behind the condition.

"Kalydeco is one of the most important advances in the treatment of cystic fibrosis since the discovery of the CF gene in 1989,” said Stuart Elborn, President of the European Cystic Fibrosis Society.

“By treating the underlying cause of the disease in people with the G551D mutation, Kalydeco helped them breathe more easily, gain weight and resulted in certain improvements in quality of life."

Vertex also declared its intentions to continue research cystic firboriss treatments for other populations.

“We're not finished," said Dr Peter Mueller, chief scientific officer and executive VP of global R&D at Vertex. "The scientists at Vertex, in collaboration with doctors, patients and advocates around the world, are working hard to develop additional new medicines to treat the underlying cause of the disease in many more people with cystic fibrosis."

30th July 2012

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Biosector 2

Biosector 2 (B2) is a global healthcare public relations agency that partners with visionary clients to deliver groundbreaking programs and...

Latest intelligence

More of the same: The importance of strategic communications planning for biosimilar entry
GCI Health's Hannah Morris considers the importance of strategic communications planning for biosimilar entry, a market anticipated to deliver between €8-26bn in savings across the European Union by 2020....
Online Physician Communities
How can pharma realise the power of digital?
Firstly, by making it owned and driven by the most senior leadership team in the business...
Remapping the market: Does Pharma's global model need a shake up?
For patients, carers and professionals, wherever they are in the world, digital technology is inherent in their everyday lives. Digital is, so to speak, a global language. The success of...